One more COVID tool for community pharmacists: https://t.co/o7xYGWRrM3
This streamlines the assessment and documentation process and aligns with the excellent AHS Tool: https://t.co/GjgFCPNbii
#COVID19#COVID19AB#TwitteRx
To support community pharmacists in patient care, I have made some prescribing, med adjustments, and renewal tools available for free. They can be accessed at https://t.co/BSw4mA9aUv (you'll need a free account to access them).
#COVID19AB#TwitterRx@ABPharmacists
The Study Buffalo Drug Price Calculator (https://t.co/3xSB6D9J1I) will unavailable intermittently on July 20 and 21 to perform upgrades - sorry for the inconvenience!
Looking forward to reading this. Wonder if this contributes to those times a pharmacist would bend over backwards to justify a strange prescribing decision rather than ask the question of the healthcare team.
Pharmacists: Upcoming paper in @CPJ_RPC: @zubin_austin shows that pharmacists have little professional identity. What does this mean? How did we get like that? What steps do we need to take? Send your responses - I will include as many as I can, with attribution, to my editorial.
This is a great proposal to improve the poster presentation by @mikemorrison. No more copy and pasted manuscripts on a PowerPoint slide! No need to be a graphic designer to create usable posters! What's not to love?
When you walk through a poster hall at a medical conference, totally overwhelmed, we all have the feeling that this poster system might be a bit broken. Here's @mikemorrison to the rescue with a plan to fix it! Latest post: https://t.co/AOugF70Lnp
Are you a Cdn who struggles to pay for your prescription drugs? I'm looking to profile patients who can't afford their meds for an upcoming feature. Pls email me: [email protected]. And spread the word. Many thanks.
@AnotherSun13@ABsteward@NEJM Doxy issue is bone penetration variable, good in jaw, not as good in long bones. No real clinical outcomes data with it. Reasonable as a fallback, but Bactrim, clinda, linezolid, quinolones much more data. See https://t.co/saQs96voP6
@NephRodby You need to make sure to use an ACE-inhibitor in combination with the CCB.
ACEi reduce incidence of edema by 38%, and reduce CCB cessation due to edema by 62%
https://t.co/PZifkR4LPq
NEW 🔥🔥🔥in CID
Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. @IDSAInfo https://t.co/QgpfLCpqjW
We need to start treating the elderly not based on age, but based on frailty.
Age is just a number.
Frailty screening tools give you a succinct snap shot.
#CSHPBanff @CSHP_Banff @Gregor_Egan
Blood pressure management delivered by pharmacists in black-owned barbershops. Great example of delivering healthcare in a team-based approach in a patient-centered manner. Also achieved some great BP reductions! #CSHPBanff
Another year and another (3) ASA primary prevention trials!
ARRIVE: no significant difference between ASA and placebo for efficacy, and increased risk of GI bleed. #CSHPBanff
However: provides more support that route of administration is not as important as ensuring you achieve sufficient blood levels to achieve pharmacodynamic efficacy.